Trial Shows Merck’s Experimental RSV Treatment Protects Infants
When it comes to protecting infants from respiratory syncytial virus (RSV), pharmaceutical giant Merck is making headlines with positive results from its recent trial of an experimental treatment called clesrovimab. This new treatment has the … Read more
